DNLI — DENALI THERAPEUTICS INC

Ownership history in XTX Topco Ltd  ·  7 quarters on record

This page tracks every 13F SEC filing in which XTX Topco Ltd reported a position in DENALI THERAPEUTICS INC (DNLI). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
0.16% (2023 Q3)
Avg. % of fund
0.07%
First filed
2021 Q1
Last filed
2025 Q3
Quarters held
7
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q3 ADDED 65,345 +51,860 +384.6% 0.05% $949K $14.52
2025 Q1 REDUCED 13,485 -2,602 -16.2% 0.01% $183K $13.60
2024 Q4 REDUCED 16,087 -28,569 -64.0% 0.03% $328K $20.38
2023 Q3 ADDED 44,656 +32,425 +265.1% 0.16% $921K $20.63
3 older quarters hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)    DNLI price (monthly, adj. close)

Other funds also holding DNLI

As of 2025 Q4 — sorted by position size

Crestline Management, LP 3Y 7Y 87.02% Lynx1 Capital Management LP 3Y 5.81% Casdin Capital, LLC 3Y 7Y 1.89% Palo Alto Investors LP 3Y 7Y 1.47% DAFNA Capital Management LLC 3Y 7Y 1.22% STEMPOINT CAPITAL LP 1.19% Monashee Investment Management LLC 3Y 7Y 0.85% Siren, L.L.C. 0.69% MASTERS CAPITAL MANAGEMENT LLC 3Y 7Y 0.67% PSP Research LLC 0.46%
← Back to XTX Topco Ltd Holdings